Loading…
The merger and private placement were announced concurrently.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics have entered into a definitive merger agreement. Concurrently, the companies announced an oversubscribed $150 million private placement.
The private placement raised $150 million in funding. The merger will combine Werewolf Therapeutics' and Ambros Therapeutics' resources and capabilities.
As of the latest data, Werewolf Therapeutics has 42,462,231 shares in free float and 48,599,066 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.